Businesswire·2026-03-13 12:03Core Viewpoint - Alto Neuroscience is actively participating in various investor conferences and has announced the completion of patient enrollment in a Phase 2 clinical trial for its drug candidate ALTO-101, aimed at treating cognitive impairment associated with schizophrenia [1][1][1] Group 1: Company Announcements - Alto Neuroscience will participate in the Stifel 2026 Virtual CNS Forum on March 17, 2026, with a live webcast available for investors [1] - The company is also set to participate in the TD Cowen 46th Annual Healthcare Conference from March 2-5, 2026, with a presentation scheduled for March 3, 2026, at 1:50 PM ET [1] Group 2: Clinical Development - Alto Neuroscience has completed patient enrollment in its Phase 2 proof-of-concept clinical trial for ALTO-101, a transdermal phosphodiesterase-4 (PDE4) inhibitor targeting cognitive impairment associated with schizophrenia [1] Group 3: Research Contributions - A review co-authored by Alto Neuroscience's leadership team has been published in the American Journal of Psychiatry, discussing neuroplasticity as a core driver of psychiatric diseases and potential treatments [1]